Top

The Egyptian Journal of Neurology, Psychiatry and Neurosurgery

Published in:

Open Access 01-12-2021 | Multiple Sclerosis | Letter to the Editor

Multiple sclerosis patients and COVID-19

Authors: Hubert Mado, Monika Adamczyk-Sowa

Published in: The Egyptian Journal of Neurology, Psychiatry and Neurosurgery | Issue 1/2021

Abstract

Coronavirus disease 2019 (COVID-19) is now a major issue for all fields of medicine. Due to the higher mortality rate among patients with chronic diseases, it has also caused concern in patients with multiple sclerosis (MS), who in addition are often receiving immunosuppressive drugs. The aim of this article is to discuss what is currently known about the severity of COVID-19 in MS patients.

Wu Z, McGoogan J. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China. JAMA. 2020;323(13):1239.CrossRef

Luna G, Alping P, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M, et al. Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurol. 2020;77(2):184.CrossRef

Adamczyk-Sowa M, Mado H, Kubicka-Bączyk K, Jaroszewicz J, Sobala-Szczygieł B, Bartman W, et al. SARS-CoV-2/COVID-19 in multiple sclerosis patients receiving disease-modifying therapy. Clin Neurol Neurosurg. 2021;201:106451.CrossRef

Louapre C, Collongues N, Stankoff B, Giannesini C, Papeix C, Bensa C, et al. Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis. JAMA Neurol. 2020;77(9):1079.CrossRef

Laroni A, Schiavetti I, Sormani M, Uccelli A. COVID-19 in patients with multiple sclerosis undergoing disease-modifying treatments. Mult Scler. 2020:135245852097181. https://doi.org/10.1177/1352458520971817. PMID: 33205695. Epub ahead of print.

Brownlee W, Bourdette D, Broadley S, Killestein J, Ciccarelli O. Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic. Neurology. 2020;94(22):949–52.CrossRef

Amor S, Baker D, Khoury S, Schmierer K, Giovanonni G. SARS-CoV -2 and multiple sclerosis: not all immune depleting DMTs are equal or bad. Ann Neurol. 2020;87(6):794–7.CrossRef

Sormani M, De Rossi N, Schiavetti I, Carmisciano L, Cordioli C, Moiola L, et al. Disease modifying therapies and COVID-19 severity in multiple sclerosis. Ann Neurol. 2021.

Abboud H, Serra A. The pressing questions in multiple sclerosis Care in the era of COVID-19. Neurol Sci. 2020;416:117005.

10.

MS Treatment Guidelines During Coronavirus [Internet]. National Multiple Sclerosis Society. 2020 [cited 29 January 2021]. Available from: https://www.nationalmssociety.org/coronavirus-covid-19-information/multiple-sclerosis-and-coronavirus/ms-treatment-guidelines-during-coronavirus. Accessed 29 Jan 2021.

Title: Multiple sclerosis patients and COVID-19
Authors: Hubert Mado
Monika Adamczyk-Sowa
Publication date: 01-12-2021
Publisher: Springer Berlin Heidelberg
Keywords: Multiple Sclerosis
COVID-19
Ocrelizumab
Ocrelizumab
Cladribine
Alemtuzumab
Alemtuzumab
Rituximab
Rituximab
SARS-CoV-2
Published in: The Egyptian Journal of Neurology, Psychiatry and Neurosurgery / Issue 1/2021
Electronic ISSN: 1687-8329
DOI: https://doi.org/10.1186/s41983-021-00287-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Multiple sclerosis patients and COVID-19

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2021

Neurological manifestations of COVID-19 infection: an umbrella review

The relationship of HLA-G 14-bp insertion/deletion genetic polymorphism to the risk of multiple sclerosis and its clinical phenotypes

Post-SARS-CoV-2 vaccination venous sinus thrombosis: a literature review of 308 cases

Diagnostic value of brain MR imaging and its correlation with clinical presentation and cognitive functions in idiopathic intracranial hypertension patients

Risk homozygous haplotype regions for autism identifies population-specific ten genes for numerous pathways

NeuroAid II (MLC901) and polypharmacy in stroke and the risk of hepatotoxicity: a case report